Clinical trials: Gastric (Stomach) Cancer
Gastric Cancer
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
This is a study for participants with advanced gastric or gastroesophageal junction adenocarcinoma who have had tumor progression after first-line platinum-contained therapy.
- Trial name
- NCT04342910
- Testing
- camrelizumab, Apatinib Mesylate, Paclitaxel
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Stomach Neoplasms, Cancer of Lymph Node
Lymph Node Metastasis in Extended Lymphadenectomy for Gastric Cancer From a CLASSIC Trial
The pattern of lymph node metastasis of the gastric cancer to each geographic lymph nose stations and the relation between each metastasis and survival are to be analyzed by retrospective review of medical records of who enrolled…
- Trial name
- NCT02298010
- Testing
- Capecitabine, oxaliplatin
- Volunteers
- 899 people
- Sponsor
- Seoul National University Hospital
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
- Trial name
- NCT05462717
- Testing
- RMC-6291
- Where
- 64 sites in United States, Australia and 11 more
- Volunteers
- 222 people
- Sponsor
- Revolution Medicines, Inc.
Advanced Gastric Cancer
Study of Endostar With Cisplatin and Capecitabine as 1st Line Treatment in the Advanced Gastric Cancer
The purpose of this study is to investigate whether endostar (recombinant human endostatin)with cisplatin and capecitabine (Xeloda) as 1st line treatment in the advanced gastric cancer is effective and safe.
- Trial name
- NCT00842491
- Testing
- endostar, cisplatin, capecitabine, capecitabine, cisplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking University
Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction
Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial
To evaluate the efficacy of maintenance therapies following completion of standard first-line chemotherapy in patients with locally advanced or metastatic HER-2 positive or HER-2 negative oesophago-gastric adenocarcinomas.
- Conditions
- Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach
- Trial name
- PLATFORM (NCT02678182)
- Testing
- Capecitabine, MEDI4736 (Durvalumab), Trastuzumab
- Where
- United Kingdom
- Volunteers
- 494 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
This phase I trial investigates the side effects and best dose of adavosertib and how well it works when given in combination with radiation therapy in treating patients with esophageal or gastroesophageal junction cancer for…
- Conditions
- Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04460937
- Testing
- Adavosertib, Radiation Therapy
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer
Learning Curve and Optimization of Robotic Gastrectomy
we explore the learning curve and the impact of technique optimization on surgical outcomes and the first to construct a referenceable learning phase for performing robotic gastric cancer surgery.
- Trial name
- NCT05715775
- Where
- China
- Volunteers
- 527 people
- Sponsor
- Fujian Medical University
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT07066657
- Testing
- MRG007, MRG007 and Bevacizumab
- Where
- 21 sites in United States, China
- Volunteers
- 572 people
- Sponsor
- ArriVent BioPharma, Inc.
Gastric Tumors
Usefulness of Near-focus With Narrow-band Imaging
Near-focus with narrow-band imaging is a novel technique to improve the quality of images of the irregular mucosal structures and microvessels of gastric neoplasms.
- Trial name
- NCT02661945
- Testing
- Near focus with narrow band imaging
- Where
- 7 sites in South Korea
- Volunteers
- 444 people
- Sponsor
- Kyunghee University Medical Center
Gastric Cancer Adenocarcinoma Metastatic
Docetaxel+Oxali+/-Cetux Met Gastric/GEJ
The purpose of this research study is to find out what effects (good and bad) docetaxel, oxaliplatin, and cetuximab have on gastric or GEJ cancer.
- Trial name
- NCT00517829
- Testing
- Docetaxel, cetuximab, oxaliplatin
- Where
- 47 sites in United States
- Volunteers
- 150 people
- Sponsor
- US Oncology Research
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Adenocarcinoma Gastric, Gastrooesophageal Cancer
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer
Primary Objectives: Part 1: to confirm the recommended tusamitamab ravtansine loading dose Q2W in combination with ramucirumab in advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma population Part 2: to assess the…
- Trial name
- CARMEN-GC01 (NCT05071053)
- Testing
- Ramucirumab (CYRAMZA®), Tusamitamab ravtansine (SAR408701)
- Where
- 21 sites in Belgium, Japan and 4 more
- Volunteers
- 35 people
- Sponsor
- Sanofi
Gastric Cancer
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ Adenocarcinoma
The purpose of the study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with PD-1 inhibitors and chemoradiotherapy, in comparison with adjuvant chemotherapy only, in D2/R0 resected pN3 gastric or…
- Trial name
- NCT04997837
- Testing
- PD-1 inhibitor, Oxaliplatin, Capecitabine
- Where
- China
- Volunteers
- 433 people
- Sponsor
- Fudan University
Advanced or Metastatic Gastric Cancer
Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests.
- Trial name
- NCT01512745
- Testing
- apatinib
- Where
- 2 sites in China
- Volunteers
- 267 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gastric Cancer
Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is a study of Camrelizumab in Combination With concurrent radiotherapy and SOX for Initial Unresectable or potentially resectable proximal Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
- Trial name
- NCT04631757
- Testing
- Camrelizumab + SOX + Radiotherapy
- Volunteers
- 33 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Stomach Neoplasms, Minimally Invasive Surgery
Intracorporeal Versus Extracorporeal Roux-en-Y Esophagojejunostomy During Laparoscopic Total Gastrectomy for Gastric Cancer
To date, Roux-en-Y esophagojejunostomy transabdominal extracorporeally by circular stapler was the most common used method during laparoscopy-assisted total gastrectomy for gastric cancer, even though it was not totally…
- Conditions
- Stomach Neoplasms, Minimally Invasive Surgery, Anastomosis
- Trial name
- NCT02085031
- Testing
- Intracorporeal Roux-en-Y esophagojejunostomy, Extracorporeal Roux-en-Y esophagojejunostomy
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Gastric Cancer
Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer
For non-esophagogastric union progressive gastric cancer, the current treatment standard is D2 surgical resection combined with postoperative adjuvant chemotherapy, and for those with advanced stage (clinical stage III or above)…
- Trial name
- NCT07085273
- Testing
- Irinotecan Liposomal
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Bleeding at Gastric Cancer
Role of Hemostatic Powder (Endo-clotTM) in Success and Prevention of Bleeding Within Gastric Cancer Patients With Bleeding
Gastrointestinal(GI) hemorrhage related with gastric cancer is prevalent in advanced cases mostly. As endoscopic hemostatic methods such as argon plasma ablation (APC) had developed, controlling GI hemorrhage in gastric cancer is…
- Trial name
- NCT02732483
- Testing
- Endo-Clot(TM)
- Where
- South Korea
- Volunteers
- 32 people
- Sponsor
- Yonsei University
Gastric Cancer
Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection
Designed as a single arm multi-center prospective phase II trial, which evaluates the number of dissected lymph nodes in the N2-area as a surrogate parameter for adequate D2 lymphadenectomy in robotic distal gastrectomy (RDG) for…
- Trial name
- AaRon (NCT02572050)
- Testing
- Distal Gastrectomy with D2 LND
- Where
- 2 sites in South Korea
- Volunteers
- 87 people
- Sponsor
- National Cancer Center, Korea
Solid Tumor
Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
The symptoms of early gastric cancer are extremely insidious and most patients are identified as advanced at the time of initial diagnosis.
- Trial name
- NCT06429891
- Testing
- 18F-FDG
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Hua Zhu
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.